Product Description
Retatrutide is a triple hormone receptor agonist targeting GIP, GLP-1, and GCGR receptors. It synergistically regulates metabolism in three dimensions—suppressing appetite, delaying gastric emptying, and increasing basal energy expenditure—by simultaneously activating glucose-dependent insulinotropic peptide receptors, glucagon-like peptide-1 receptors, and glucagon receptors. This unique triple-target mechanism demonstrates far greater potential than existing single- or dual-target drugs in weight loss, glycemic control, and improvement of metabolic-related fatty liver.
Product Advantages
Proponents of Retatrutide believe its synergistic triple-target action has the potential to redefine the standard of care for obesity and related metabolic diseases. Its core principle lies in its ability to address the two fundamental causes of obesity simultaneously: excessive intake and insufficient expenditure.
Weight Loss Efficacy: The Phase III TRIUMPH-1 study showed that in obese or overweight adults without type 2 diabetes, once-weekly subcutaneous injections of 12 mg resulted in an average weight loss of 28.3% after 80 weeks, with over 60% of participants experiencing weight loss exceeding 25%.
Metabolic-related fatty liver: Because the GCGR target can directly promote hepatic lipid oxidation, researchers are exploring the potential of retatrutide in improving non-alcoholic fatty liver disease. Data shows that approximately 90% of patients in the highest dose group had their liver fat content return to normal.
Type 2 diabetes: Retatrutide can significantly improve glycemic control. Related studies show that the highest dose group experienced an average reduction of approximately 2.1% in HbA1c, with some patients achieving diabetic remission.
Cardiovascular metabolic improvement: Researchers are working to comprehensively improve cardiovascular risk factors, such as blood pressure and blood lipids, which may bring additional health benefits beyond weight loss to obese patients.